drugset
drugset / Trial / NCT01380509

Bioavailability Study of Metronidazole Capsules Under Fasting Conditions

NCT01380509 ↗

Phase 1 Completed 28 enrolled Par Pharmaceutical, Inc. Algorithme Pharma Inc · collab
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to compare the single-dose Bioavailability of Kali and G.D. Searle, Inc.

Timeline

Start
2002-08
Primary completion
2002-09
Completion
2002-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule 375 mg —

Indications

No indication recorded.